Format

Send to

Choose Destination
Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Author information

1
Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France. mohamad.mohty@inserm.fr.
2
Clinical Research Division, Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
3
Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France.
4
Oncology Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
5
Department of Internal Medicine/ American University of Beirut, Beirut, Lebanon.
6
Institut Paoli-Calmettes, Inserm CBT-1409 & Aix-Marseille Université, Marseille, France.
7
Blood and Marrow Transplantation Program, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
8
Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
9
Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Institute of Hematology, Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 310058, China.
10
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
11
The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
12
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
13
Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

PMID:
31690821
DOI:
10.1038/s41375-019-0615-5

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center